Q-omics provides the consensus-scored ATP5PDP2 profile across patient tissues and cancer cell-line models. ATP5PDP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ATP5PDP2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, ATP5PDP2 RNA expression shows 9,281 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight THCA, LUAD, and OV as cancer lineages where ATP5PDP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PDP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PDP2 survival associations across molecular data types. ATP5PDP2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PDP2 RNA expression–survival associations across cancer types. High ATP5PDP2 expression shows unfavorable associations in LUAD, ACC, THYM and KICH, but favorable associations in THCA and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for ATP5PDP2 RNA expression.
This table summarizes ATP5PDP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5PDP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PDP2 shows lower tumor expression in THCA and STAD and higher tumor expression in LUAD, KIRP, COAD and BRCA. The LUAD box plot shows higher ATP5PDP2 RNA expression in tumor versus normal tissue (log2 FC = +0.149, t-test p = .001).
This table shows molecular features associated with ATP5PDP2 in patient tissues and cancer cell lines. In patient samples, ATP5PDP2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
